Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy
PHASE2CompletedINTERVENTIONAL
Enrollment
130
Participants
Timeline
Start Date
April 30, 2019
Primary Completion Date
March 16, 2021
Study Completion Date
July 23, 2021
Conditions
Tuberculosis
Interventions
DRUG
Rifampin 300 Mg Oral Capsule
High dose rifampicin at 35mg/kg
Trial Locations (1)
256
Infectious Diseases Institute, Kampala
All Listed Sponsors
lead
Makerere University
OTHER
NCT03982277 - Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy | Biotech Hunter | Biotech Hunter